The $300 billion pharmaceutical industry is a major economic driver in Tennessee through clinical studies funded by drugmakers, PhRMA Senior Director of Public Affairs Jeff Trewhitt was set to tell Tennessee's House Health Committee. "We may not have a large brick and mortar presence in Tennessee, but we have a profound impact," he said. Drugmakers have funded 464 active studies in the state involving the six top chronic illnesses. The costs of these studies are going directly to research institutes such as Sarah Cannon, Meharry and Vanderbilt, Trewhitt said.

Related Summaries